The Growing Burden of Uncontrolled T2DM in India

Current Statistics on Diabetes in India

The prevalence of diabetes in India has significantly increased, yet only approximately 7% of individuals diagnosed with Type 2 Diabetes Mellitus (T2DM) achieve the combined treatment targets for A1c (glycated hemoglobin), blood pressure, and cholesterol levels. National data reveals that 34.5% of those with diagnosed T2DM have inadequately controlled blood glucose levels. Glycemic control is notably challenging to maintain and often begins to decline as early as five years after diagnosis, underscoring the importance of timely treatment intensification. These statistics emphasize the urgent necessity for early, multifaceted interventions to mitigate complications.

Considering Early Combination Triple Therapy in Uncontrolled T2D

Rationale for Early Combination Therapy

Given the progressive nature of β-cell dysfunction and insulin resistance in T2DM, initiating early combination therapy can effectively address the glycemic inertia often associated with gradual treatment approaches. Landmark studies have demonstrated that starting treatment with multiple agents early on offers long-term benefits, resulting in improved durability of glycemic control compared to metformin monotherapy. This article will explore the rationale behind early combination strategies, particularly the use of Metformin, Sitagliptin, and Empagliflozin.

Mechanisms of Action of Each Agent

  • Metformin: In addition to its insulin-sensitizing effects, Metformin provides direct protective actions on pancreatic β cells by preserving their function and viability. It also benefits cardiac health by reducing oxidative stress-induced cardiomyocyte apoptosis and fibrosis.
  • Sitagliptin: Sitagliptin enhances glycemic control and preserves β-cell function by amplifying the actions of GLP-1 and GIP. It is weight-neutral and cardiovascular safe, supporting β-cell health through GIP-mediated mechanisms.
  • Empagliflozin: Empagliflozin promotes glucosuria by selectively inhibiting SGLT2 in the renal proximal tubule, leading to sustained glucose lowering and weight loss through urinary caloric loss. Its mild diuretic effect also contributes to blood pressure reduction. By functioning independently of β-cells, empagliflozin reduces glucotoxicity and is associated with lower rates of cardiovascular-related hospitalization and mortality.

Clinical Snapshot: Evidence for Triple Combination Therapy

A two-year prospective study involving 170 drug-naïve patients with newly diagnosed T2DM (baseline HbA1c of 11.0%±1.8%) indicated that initial triple therapy with metformin 1,000 mg/day, sitagliptin 100 mg/day, and empagliflozin 10 mg/day resulted in a significant reduction in HbA1c levels to 7.0%±1.7%.